ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR) | Rumor.io

Arrowhead Pharmaceuticals

ARWR

Attention (50-day avg)0%

Attention rank (50-day avg)#685

Bullish sentiment (50-day avg)70%

Price to earnings ratio47.1

Market capitalization9.2B

Earnings per share-2.28

Dividend yield (TTM)—

Revenue (annual)829.4M

Net income (annual)30.1M

Social

What share of all stock conversation is about ARWR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.01% +0	0% 0

Sep 23

The company has announced Phase 3 data for its SHASTA-3/4 program, with a planned filing for the SHINGRIX vaccine.
The stock is experiencing its worst day in over a year despite positive data on its cholesterol-lowering drug, leading to speculation on whether it's a "sell the news" move.
The company is expected to release MAPT data via a press release before its conference on September 25th, with some investors skeptical about the timing of the release.

Generated by AI

Sentiment

Of the messages about ARWR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	33.33% -34.44	63.79% -31.83	83.3% +6.71
Bearish	100%	66.67% +34.44	36.21% +31.83	16.7% -6.71

Bullish· Jul 23

H.C. Wainwright reiterated a Buy recommendation for ARWR with a price target of $100, citing positive topline readouts from SHASTA-3 and SHASTA-4 trials that de-risk the expansion into the severe hypertriglyceridemia population.
Morgan Stanley raised the price target for ARWR to $120, highlighting the stock's potential for continued growth.
ARWR gapped up by 20.3% at the open, reaching a 5-year high, as investors react to the promising clinical data for Plozasiran.

Bearish· Sep 15

The asset's price dropped by around 11.99% due to a clinical data readout from its Phase 1/2a trial, which may indicate that the data is not as positive as expected.
The market's reaction to the data readout was seen as "manipulated price action" and "fake", with some users accusing the market of being "dumb" and others noticing a pattern of price drops around quarterly expirations dates.
The asset's price has been affected by its beta value, with the user noting that it has a high beta only on downward pressure, and that the market's reaction to the data readout was not in line with the expected price action.

Generated by AI

Topics

Of the messages about ARWR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	51.06%	91.07%	72.89%
Analysts	0%	48.94%	8.77%	14.64%
Technical Analysis	0%	0%	0.15%	5.57%
Earnings	0%	0%	0%	1.39%
Controversies	0%	0%	0%	3.12%
Macro	0%	0%	0%	2.39%

Earnings· Aug 7

Arrowhead Pharmaceuticals (ARWR) reported Q3 EPS of -$0.18, in-line with estimates.
The company's revenue of $0.72M beat estimates by $0.03M, despite a 92.3% year-over-year decline.
ARWR's earnings results beat the Estimize EPS and revenue consensus by 1c and $0.20M, respectively.

Analysts· Apr 21

Morgan Stanley upgraded Arrowhead Pharmaceuticals (ARWR) to Overweight from Equal Weight and raised its price target to $100 from $78, citing major catalysts expected from the California-based biotech over the next 12 months.
Morgan Stanley sees significant upside driven by upcoming Phase 3 data and higher revenue expectations for plozasiran, a key drug in Arrowhead Pharmaceuticals' pipeline.
Arrowhead Pharmaceuticals' shares rose 4.1% on the upgrade to Overweight from Morgan Stanley, with the firm setting a price target of $100.

Announcements· Jul 23

H.C. Wainwright reiterated a Buy rating for ARWR with a price target of $100, citing positive topline readouts from SHASTA-3 and SHASTA-4 trials.
Arrowhead Pharmaceuticals announced they will present P3 Hypertriglyceridemia results on August 30, 2026, for Plozasiran.
Arrowhead Pharmaceuticals presented P3 Hypertriglyceridemia results on July 22, 2026, for Plozasiran.

Controversies· Sep 11

Arrowhead Pharmaceuticals (ARWR) has filed a complaint for declaratory judgment against Ionis Pharmaceuticals (IONS) to invalidate Ionis's patent related to RNAi candidate Tryngolza.
The dispute revolves around Arrowhead's drug Plozasiran, which is under FDA review for a genetic disorder, and Ionis's claim that it infringes on their patent.
Arrowhead is seeking a ruling that Plozasiran does not infringe on Ionis's patent, and that the patent is invalid, which could have significant implications for the development of both companies' drugs.

Technical Analysis· Dec 3

The stock has shown incredible strength, and a buy may be considered above the 5 EMA.
A buy signal was confirmed after the MACD signal and the stock price broke through previous resistance levels.
The price action has shifted bullish, with increased volume and a short float of 9.21%, indicating meaningful short exposure.

Generated by AI

Community

Of the messages about ARWR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	86.67%	81.51%	88.67%	82.07%
Newcomers	13.33%	18.49%	11.33%	17.93%

Regulars· Sep 17

The CEO's emphasis on the pipeline/platform driving value has been overlooked by investors, potentially missing the next big opportunity.
The recent 24% stock price drop in the last 4 weeks is puzzling, with some analysts attributing it to unrealistic expectations and others pointing to the massive pipeline's potential for a substantial buyout or partnering deal.
The company's clinical success rate, translation from P1 to P2, and safety profile have been best-in-class, making it an attractive candidate for partnering or buyout deals, with a minimum value of $200/sh for a realistic buyout consideration.

Newcomers· Jul 23

The newcomer is focused on the Phase 3 win of $ARWR, highlighting significant triglyceride reductions and a strong FDA path.
The price target for $ARWR has been raised to $120 from $100 at Morgan Stanley, indicating a bullish outlook for the asset.
The newcomer is also focused on the retail community's enthusiasm for $ARWR, with one user suggesting it's a classic runner play and another asking if others are catching the move or waiting.

Generated by AI

News

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

1d agoYahoo Finance

ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?

ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.

14d agoYahoo Finance

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

PASADENA, Calif., September 15, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP

15d agoYahoo Finance

Also Discussed

Investors talking about ARWR also mention

#	Name	Attention
1	Alnylam Pharmaceuticals, Inc.ALNY	0%0
2	Ionis Pharmaceuticals, Inc.IONS	0%new
3	Arbutus Biopharma CorporationABUS	0%0
4	Wave Life Sciences Ltd.WVE	0%+0
5	Fate Therapeutics Inc.FATE	0%new
6	AFMD - Affimed N.V.	——
7	BioMarin Pharmaceutical IncBMRN	0%+0
8	ProQR Therapeutics N.V. Ordinary SharesPRQR	0%0
9	Sarepta Therapeutics, Inc.SRPT	0%-0.01
10	FOLD - Amicus Therapeutics, Inc.	——

Arrowhead Pharmaceuticals, Inc.

Healthcare
Biotechnology

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.

Website

Location

177 East Colorado Boulevard

Pasadena, CA, 91105

United States

Social

What share of all stock conversation is about ARWR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0.01% +0	0% 0

Sep 23

The company has announced Phase 3 data for its SHASTA-3/4 program, with a planned filing for the SHINGRIX vaccine.
The stock is experiencing its worst day in over a year despite positive data on its cholesterol-lowering drug, leading to speculation on whether it's a "sell the news" move.
The company is expected to release MAPT data via a press release before its conference on September 25th, with some investors skeptical about the timing of the release.

Generated by AI

Sentiment

Of the messages about ARWR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	33.33% -34.44	63.79% -31.83	83.3% +6.71
Bearish	100%	66.67% +34.44	36.21% +31.83	16.7% -6.71

Bullish· Jul 23

H.C. Wainwright reiterated a Buy recommendation for ARWR with a price target of $100, citing positive topline readouts from SHASTA-3 and SHASTA-4 trials that de-risk the expansion into the severe hypertriglyceridemia population.
Morgan Stanley raised the price target for ARWR to $120, highlighting the stock's potential for continued growth.
ARWR gapped up by 20.3% at the open, reaching a 5-year high, as investors react to the promising clinical data for Plozasiran.

Bearish· Sep 15

The asset's price dropped by around 11.99% due to a clinical data readout from its Phase 1/2a trial, which may indicate that the data is not as positive as expected.
The market's reaction to the data readout was seen as "manipulated price action" and "fake", with some users accusing the market of being "dumb" and others noticing a pattern of price drops around quarterly expirations dates.
The asset's price has been affected by its beta value, with the user noting that it has a high beta only on downward pressure, and that the market's reaction to the data readout was not in line with the expected price action.

Generated by AI

Topics

Of the messages about ARWR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	51.06%	91.07%	72.89%
Analysts	0%	48.94%	8.77%	14.64%
Technical Analysis	0%	0%	0.15%	5.57%
Earnings	0%	0%	0%	1.39%
Controversies	0%	0%	0%	3.12%
Macro	0%	0%	0%	2.39%

Earnings· Aug 7

Arrowhead Pharmaceuticals (ARWR) reported Q3 EPS of -$0.18, in-line with estimates.
The company's revenue of $0.72M beat estimates by $0.03M, despite a 92.3% year-over-year decline.
ARWR's earnings results beat the Estimize EPS and revenue consensus by 1c and $0.20M, respectively.

Analysts· Apr 21

Morgan Stanley upgraded Arrowhead Pharmaceuticals (ARWR) to Overweight from Equal Weight and raised its price target to $100 from $78, citing major catalysts expected from the California-based biotech over the next 12 months.
Morgan Stanley sees significant upside driven by upcoming Phase 3 data and higher revenue expectations for plozasiran, a key drug in Arrowhead Pharmaceuticals' pipeline.
Arrowhead Pharmaceuticals' shares rose 4.1% on the upgrade to Overweight from Morgan Stanley, with the firm setting a price target of $100.

Announcements· Jul 23

H.C. Wainwright reiterated a Buy rating for ARWR with a price target of $100, citing positive topline readouts from SHASTA-3 and SHASTA-4 trials.
Arrowhead Pharmaceuticals announced they will present P3 Hypertriglyceridemia results on August 30, 2026, for Plozasiran.
Arrowhead Pharmaceuticals presented P3 Hypertriglyceridemia results on July 22, 2026, for Plozasiran.

Controversies· Sep 11

Arrowhead Pharmaceuticals (ARWR) has filed a complaint for declaratory judgment against Ionis Pharmaceuticals (IONS) to invalidate Ionis's patent related to RNAi candidate Tryngolza.
The dispute revolves around Arrowhead's drug Plozasiran, which is under FDA review for a genetic disorder, and Ionis's claim that it infringes on their patent.
Arrowhead is seeking a ruling that Plozasiran does not infringe on Ionis's patent, and that the patent is invalid, which could have significant implications for the development of both companies' drugs.

Technical Analysis· Dec 3

The stock has shown incredible strength, and a buy may be considered above the 5 EMA.
A buy signal was confirmed after the MACD signal and the stock price broke through previous resistance levels.
The price action has shifted bullish, with increased volume and a short float of 9.21%, indicating meaningful short exposure.

Generated by AI

Community

Of the messages about ARWR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	86.67%	81.51%	88.67%	82.07%
Newcomers	13.33%	18.49%	11.33%	17.93%

Regulars· Sep 17

The CEO's emphasis on the pipeline/platform driving value has been overlooked by investors, potentially missing the next big opportunity.
The recent 24% stock price drop in the last 4 weeks is puzzling, with some analysts attributing it to unrealistic expectations and others pointing to the massive pipeline's potential for a substantial buyout or partnering deal.
The company's clinical success rate, translation from P1 to P2, and safety profile have been best-in-class, making it an attractive candidate for partnering or buyout deals, with a minimum value of $200/sh for a realistic buyout consideration.

Newcomers· Jul 23

The newcomer is focused on the Phase 3 win of $ARWR, highlighting significant triglyceride reductions and a strong FDA path.
The price target for $ARWR has been raised to $120 from $100 at Morgan Stanley, indicating a bullish outlook for the asset.
The newcomer is also focused on the retail community's enthusiasm for $ARWR, with one user suggesting it's a classic runner play and another asking if others are catching the move or waiting.

Generated by AI

Arrowhead Pharmaceuticals

Social

Sep 23

Bullish· Jul 23

Bearish· Sep 15

Earnings· Aug 7

Analysts· Apr 21

Announcements· Jul 23

Controversies· Sep 11

Technical Analysis· Dec 3

Regulars· Sep 17

Newcomers· Jul 23

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

Arrowhead Achieves Clinical Validation for New Drug Platform

ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Also Discussed

Arrowhead Pharmaceuticals, Inc.

Company Information

Location

Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Goldman Sachs initiates Arrowhead Pharma stock coverage with neutral rating

Arrowhead Pharmaceuticals Eyes SHTG Filing as RNAi Pipeline Expands

Arrowhead Achieves Clinical Validation for New Drug Platform

ARWR Stock Heads For Worst Day In Over A Year Despite Positive Cholesterol Drug Data — Is This A ‘Sell The News’ Move?

Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

Also Discussed

Social

Sep 23

Bullish· Jul 23

Bearish· Sep 15

Earnings· Aug 7

Analysts· Apr 21

Announcements· Jul 23

Controversies· Sep 11

Technical Analysis· Dec 3

Regulars· Sep 17

Newcomers· Jul 23